healthcare transparency – The Milli Chronicle

Wednesday, December 17, 2025

Latest:

Factual Version of a Story

Featured News World

NewsDesk Milli Chronicle December 16, 2025December 16, 2025 clinical risk assessment, diabetes medication law, drug safety oversight, drug side effects review, Eli Lilly litigation, federal court consolidation, GLP-1 lawsuits, healthcare legal process, healthcare transparency, medical product liability, modern medicine regulation, multidistrict litigation, Novo Nordisk claims, Ozempic legal cases, patient protection policy, patient safety law, pharmaceutical accountability, pharmaceutical litigation, vision loss allegations, weight loss drug safety

Courts Streamline GLP-1 Drug Lawsuits to Support Clarity and Patient Safety

Centralized review aims to ensure consistent, transparent handling of emerging claims. Federal courts have taken a structured step to manage

Featured News World

NewsDesk Milli Chronicle November 13, 2025November 13, 2025 digital health, drug partnership denial, drug safety, Eli Lilly, Eli Lilly news, fake weight-loss drugs, GLP-1 treatments, healthcare transparency, Mangoceuticals, Mounjaro, Novo Nordisk, Novo Nordisk news, obesity drug market, obesity drugs, obesity treatment market, online pharmacy safety, pharmaceutical industry, telehealth company, telemedicine, Wegovy, weight loss medication, Zepbound

Novo Nordisk and Eli Lilly Reject Claims of Partnership with Mangoceuticals on Obesity Drugs

Novo Nordisk and Eli Lilly clarify that they have no collaboration or special arrangement with telehealth firm Mangoceuticals, following misleading

Featured News World

NewsDesk Milli Chronicle November 4, 2025 Center for Drug Evaluation and Research, clinical trials, drug approval process, drug safety, ethical governance, FDA ethics, FDA leadership change, FDA modernization, FDA reform, Food and Drug Administration, global drug safety, health policy, healthcare transparency, medical innovation, medical research, pharmaceutical innovation, pharmaceutical regulation, public health, Robert F. Kennedy Jr., U.S. health agencies, US FDA

US FDA’s Drug Division Undergoes Leadership Transition to Strengthen Integrity and Innovation

The U.S. Food and Drug Administration begins a new chapter in its drug evaluation and research division, focusing on ethics,